SuperworthElanco Animal Health free cash flow ELAN
Cash from operations less capital spending, by quarter and over the last twelve months, from 2017.
- Last 12 months, to Jun 30, 2026
- $379M
- Latest quarter, Q2 FY26
- $244M
- +36% on a year earlier
- Fiscal year 2025
- $284M
- −28% on the year before
Elanco Animal Health's free cash flow was $379M over the twelve months to Jun 30, 2026, up 5% on a year earlier.
In its latest quarter, Q2 FY26, it was $244M, up 36% on the same quarter a year before.
Free cash flow over time
Fiscal year by fiscal year
| Fiscal year | Free cash flow | Change |
|---|---|---|
| FY2025 | $284M | −28% |
| FY2024 | $394M | +201% |
| FY2023 | $131M | −55% |
| FY2022 | $294M | −18% |
| FY2021 | $357M | n/a |
| FY2020 | n/a | n/a |
| FY2019 | $47.5M | −87% |
| FY2018 | $352.8M | n/a |
| FY2017 | n/a | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | Free cash flow | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | $244M | +36% | $379M | |
| Q1 FY26 | −$38M | n/a | $315M | |
| Q4 FY25 | $46M | −65% | $284M | |
| Q3 FY25 | $127M | +6% | $368M | |
| Q2 FY25 | $180M | +8% | $361M | |
| Q1 FY25 | −$69M | n/a | $347M | |
| Q4 FY24 | $130M | +12% | $394M | |
| Q3 FY24 | $120M | −27% | $380M | |
| Q2 FY24 | $166M | +774% | $425M | |
| Q1 FY24 | −$22M | n/a | $278M | |
| Q4 FY23 | $116M | n/a | $131M | |
| Q3 FY23 | $165M | +8% | −$49M |
Against its peers
Companies in Drug Manufacturers - General nearest Elanco Animal Health's size, closest first, today.
| Company | Free cash flow yield |
|---|---|
| ELANElanco Animal Health | 3.4% |
| BMRNBiomarin Pharmaceutical | 6.8% |
| CORTCorcept Therapeutics | 1.2% |
| JAZZJazz Pharmaceuticals | 11.5% |
| PTGXProtagonist Therapeutics | 1.5% |
| TGTXTG Therapeutics | 0.2% |
| ALKSAlkermes plc. | 3.0% |
| AMRXAmneal Pharmaceuticals | 2.0% |
| LGNDLigand Pharmaceuticals | 2.2% |
| KNSAKiniksa Pharmaceuticals International | 3.1% |
| INDVIndivior Pharmaceuticals | −2.7% |
| Peer median | 2.1% |
Where Elanco Animal Health ranks
What the free cash flow tells you
Cash from operations minus capital spending. The cash the company could hand back or reinvest.
Seasonal and lumpy quarter to quarter. The TTM view is the one to trust.
More on Elanco Animal Health
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.